GlassScriptPhysician profile
Danilo Pangilinan
NPI 1184691800
$13,035.24
in general payments reported to CMS, 2019-2025
51 companies · $2,037 in 2025
The $2,037 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,767 · 2020: $1,074 · 2021: $1,374 · 2022: $1,270 · 2023: $1,660 · 2024: $1,854 · 2025: $2,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,544 · Education: $5.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,544.42 |
| Education | $5.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,516.08 | 2019-2025 | Breztri, Airsupra, Bevespi Aerosphere |
| Novo Nordisk INC | $1,266.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $888.72 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $745.35 | 2019-2025 | Mounjaro, Zepbound, Lyumjev |
| Janssen Pharmaceuticals, INC | $720.41 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $697.77 | 2019-2025 | Veozah, Myrbetriq |
| E.R. Squibb & Sons, L.L.C. | $593.81 | 2020-2025 | Eliquis |
| Abbvie INC. | $489.37 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $446.59 | 2019-2025 | |
| Pfizer INC. | $432.17 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $327.44 | 2019-2025 | |
| Allergan, INC. | $318.56 | 2019-2020 | |
| Amarin Pharma, INC. | $317.24 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $292.85 | 2020-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $283.37 | 2019-2025 | Xifaxan |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $262.21 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $252.79 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $224.70 | 2019-2025 | Lagevrio, Gardasil 9, Capvaxive |
| Esperion Therapeutics, INC. | $192.63 | 2021-2025 | Nexletol |
| Abbott Laboratories | $149.20 | 2019 | |
| Boston Scientific Corporation | $148.75 | 2019-2025 | Watchman Access System |
| Kowa Pharmaceuticals America, INC. | $147.82 | 2019-2025 | Zoryve |
| Ardelyx, INC. | $128.14 | 2025 | Ibsrela |
| Lundbeck LLC | $127.17 | 2024-2025 | Rexulti |
| Mylan Specialty L.P. | $125.10 | 2019 | |
| Amgen INC. | $112.30 | 2019 | |
| Gilead Sciences, INC. | $81.08 | 2019 | |
| Ironwood Pharmaceuticals, INC | $69.75 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $65.94 | 2023-2025 | Nuedexta, Rexulti |
| Phathom Pharmaceuticals, INC. | $57.70 | 2025 | Voquezna |
| Shield Therapeutics INC | $47.69 | 2023-2024 | Accrufer |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.11 | 2024-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $42.07 | 2022 | |
| Seqirus USA INC | $39.02 | 2019-2025 | Flucelvax, Fluad |
| Philips North America LLC | $37.22 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Neurocrine Biosciences, INC. | $31.60 | 2023 | Ingrezza |
| Bayer Healthcare Pharmaceuticals INC. | $30.97 | 2025 | |
| Inspire Medical Systems, INC. | $27.66 | 2024 | Inspire |
| Indivior INC. | $23.62 | 2025 | Sublocade |
| Intra-Sana Laboratories | $23.57 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Braeburn INC. | $23.04 | 2024 | Brixadi |
| Eisai INC. | $22.05 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.44 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.92 | 2019 | |
| Hikma Pharmaceuticals USA | $18.03 | 2022 | |
| Alkermes, INC. | $18.02 | 2019 | |
| Echosens North America, INC. | $17.76 | 2025 | Fibroscan |
| Actelion Pharmaceuticals US, INC. | $17.63 | 2025 | Opsumit, Uptravi |
| Currax Pharmaceuticals LLC | $16.94 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $16.59 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danilo Pangilinan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.